Interim Analysis Results from a Pivotal Randomized Trial of AV Access in Women

Join the SVS Women's Section for an exclusive educational webinar featuring the 12-month interim analysis of the CLN-PRO-V012 study—a multicenter, randomized Phase 3 trial evaluating a novel acellular tissue-engineered vessel (ATEV) compared with autogenous arteriovenous fistula (AVF) for hemodialysis vascular access in women with end-stage kidney disease.

Women experience lower rates of AVF maturation, greater catheter dependence and higher rates of vascular access complications than men. Despite these disparities, prospective randomized studies designed specifically to address this unmet need have been limited. The CLN-PRO-V012 trial was developed to evaluate vascular access outcomes in women receiving hemodialysis who are at increased risk of AVF maturation failure.

During this one-hour webinar, Humacyte will present the complete 12-month interim analysis, including:

• Efficacy and safety outcomes
• Clinical interpretation of the findings
• Potential implications for future vascular access strategies in women at increased risk of AVF maturation failure

Don't miss this opportunity to hear the latest evidence and explore how these findings may help shape the future of vascular access care for women.

This webinar is free to attend. After clicking "register now," to complete registration, you’ll need to login to your SVS member account. If you’re not an SVS member, simply create a free account to continue.

This webinar is the sole content of the Industry Sponsor and does NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies, or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.